MPO250, a bispecific VEGF/HGF-targeting DARPin®, was administered with bortezomib and dexamethasone to 20 highly pretreated relapsed/refractory MM patients in the MiRRoR Study [253]. Here, HGF is linked to Miyoshi myopathy.